Mergers & acquisitions
Since the acquisition fell apart, Allergan has fallen on some hard times.
Will this new buy be enough for Celgene investors?
The offers underline Novo Nordisk’s interest in expanding beyond diabetes and into the rare diseases market.
The company said it will acquire Impact Biomedicines and its JAK inhibitor program targeting myelofibrosis.
Rumors that Acorda was considering a sale drove company stock up about 12 percent on Friday, Jan. 5, to hit $23.55.
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
Xinogen will make upfront and milestone payments and also pay royalties on sales, though specific details were not disclosed.
The nearly 100-year-old medical-device business manufactures prosthetics and orthotics such as foot inserts and knee braces.
Both companies are noted for growth through acquisition, and 2017 has been a very big year for LabCorp.
The group has bought 11 businesses in the past seven years.
PRESS RELEASES